Reports Q2 revenue $18.17M, consensus $4.21M. “The second quarter marked an important point for Keros, as Keros’ Board of Directors completed its comprehensive strategic review,” said Jasbir Seehra, Chair and Chief Executive Officer. “Following the review, our focus remains on creating long-term value through advancing the development of our pipeline of novel therapeutics, including our lead asset, KER-065, which the team is progressing towards initiation of a Phase 2 clinical trial in patients with Duchenne muscular dystrophy in the first quarter of 2026.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics Begins Phase 3 Trial for Elritercept
- Keros Therapeutics announces first patient dosed in Phase 3 RENEW trial
- Keros Therapeutics Announces CMO Resignation
- McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls
- Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside